Dragonfly Therapeutics

Immuno-oncology Drugs

DF6002 Clin1 solid tumors; DF9001 Clin1 solid tumors; DF2001 Clin1 leukemia (partner: BMS); DF3001 Clin1 multiple myeloma (partner: BMS); 13+ additional programs RD/Clin0 oncology, undisclosed

Dragonfly Therapeutics is harnessing the innate immune system to develop novel immunotherapies to treat disease. Natural killer cells (NK) are employed in the body to recognise and kill cancer cells. Dragonfly is using their two proprietary platforms to create a portfolio of drugs that can activate and boost NK cell activity for therapeutic use. The first is TriNKETTM, tri-specific NK cell engagers that can trigger the cell's activity against cancer cells. The second is CYTOKINEs which fuel the NK cells activity. Dragonfly currently has six drugs in clinical trials, with their lead candidate, DF1001, in Phase 2 for patients with advanced solid tumors.